All 504 statin-nave ACS patients enrolled in the PRATO-ACS ( Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in ACS Patients ) study were stratified into baseline hs-CRP tertiles : < 2.7 mg/l , 2.7 to < 7.5 mg/l , and 7.5 mg/l .